Commentary

TAG Paper: Observations on Drug Pricing and Innovation in Japan

Full Paper (English): TAG Paper: Observations on Drug Pricing and Innovation in Japan ENG

Full Paper (Japanese): TAG Paper: Observations on Drug Pricing and Innovation in Japan JPN

Key Findings

As the Government of Japan (GOJ) seeks to re-invigorate Japan’s pharmaceutical industry as a sector for innovation and growth, it can make impactful changes to specific pricing policies that will support Japanese patients’ access to the most innovative medicines.

The Asia Group (TAG) has identified two specific pharmaceutical pricing measures that directly undermine the government’s goal of promoting startups and bringing innovative new pharmaceutical products to market. The negative impact of these policies is particularly severe for innovative drugs for rare diseases, for which there are often no alternative treatments:

  1. Strict cost disclosure requirements, especially the “co-factor zero” rule introduced in the cost-based price calculation method in 2022, are effectively canceling out many premiums that were intended to reward innovation and novelty.
  2. Corporate status criteria associated with the Price Maintenance Premium (PMP) system favor companies with a long track record of business in Japan and limit premium benefits for new market entrants.

The intended purpose of these rules is to improve transparency in a product’s total cost and provide incentives for drug launches in Japan. But the two-fold impact of these rules, particularly penalizing new market entrants and foreign entrants, has undermined the intended effect of these measures.

Eliminating these two specific punitive pricing policies represents “low-hanging fruit” for policy change, which can have an immediate impact on the availability of novel drugs, while having a relatively low impact on Japan’s healthcare budget. These changes will stimulate future successful launches and early entrance to Japan, benefitting patients.

Related Posts

TAG China Country Director, Han Lin, Comments in the Financial Times About the Significance of China Hosting the World Economic Forum “Summer Davos”
“China’s hosting of ‘Summer Davos’ amplifies how it wants to see and be seen by the international community as the ...
TAG China Country Director Han Lin Speaks at the World Economic Forum “Summer Davos” Held in Tianjin, China
Han Lin, China Country Director at The Asia Group, participated in a panel discussion and led a breakout session on ...
TAG Chairman and Co-Founder, The Hon. Dr. Kurt Campbell Shares Thoughts on U.S.-China Relations in Interview with Bloomberg
“The steps that Treasury Secretary Bessent has taken, with his [Chinese] counterpart, the Vice Premier, at least appear to be ...
TAG Partner Amb. Dan Kritenbrink Participates in Panel on U.S.-Vietnam Relations
Ambassador Dan Kritenbrink, Partner at The Asia Group, participated in a panel discussion hosted by the US-ASEAN Center, the Vietnam ...
Scroll to Top

You Are Applying For:

TAG Paper: Observations on Drug Pricing and Innovation in Japan

Apply Now

Submit the details below, and our HR team member will get in touch with you shortly.

The Asia Group is an equal opportunity employer where an applicant’s qualifications are considered without regard to race, color, religion, sex, national origin, age, disability, veteran status, genetic information, sexual orientation, gender identity or expression, or any other basis prohibited by law. The Asia Group continually seeks to diversify its staff, particularly to broaden opportunities for individuals from demographic groups that are historically underrepresented in the strategic advisory profession.

"*" indicates required fields

1Personal Details
2Questionnaire & Application Materials
3Voluntary Self Identification

Personal Details

Name*
Address*